August 4, 2020
Kyorin Holdings will grant exclusive worldwide rights for its novel compound to treat sensorineural hearing loss to Otonomy, a San Diego-based biopharma specializing in neurotology, the two companies said in separate statements on August 3. Under the deal, the US...read more